• 1. Agonistic or antagonistic mucosal-associated invariant T (MAIT) cell activity is determined by the 6-alkylamino substituent on uracil MR1 ligands
  Chriselle D. Braganza,Chihiro Motozono,Koh-Hei Sonoda,Sho Yamasaki,Kensuke Shibata,Mattie S. M. Timmer,Bridget L. Stocker Chem. Commun. 2020 56 5291
• 2. The effect of MR1 ligand glyco-analogues on mucosal-associated invariant T (MAIT) cell activation
  Chriselle D. Braganza,Kensuke Shibata,Aisa Fujiwara,Chihiro Motozono,Koh-Hei Sonoda,Sho Yamasaki,Bridget L. Stocker,Mattie S. M. Timmer Org. Biomol. Chem. 2019 17 8992

Introduction to 2-Acetamido-6-formylpteridin-4-one (CAS No. 29769-49-1)

2-Acetamido-6-formylpteridin-4-one, with the chemical identifier CAS No. 29769-49-1, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This heterocyclic organic molecule belongs to the pteridine family, which is well-documented for its diverse biological activities and potential therapeutic applications. The unique structural features of this compound, including the presence of an acetamido group and a formyl substituent, make it a valuable intermediate in synthetic chemistry and a promising candidate for further biochemical investigation.

The pteridine core of 2-Acetamido-6-formylpteridin-4-one is a nitrogen-containing aromatic ring system that is widely recognized for its role in various physiological processes. Pteridines and their derivatives have been extensively studied for their involvement in enzymatic reactions, cellular signaling, and metabolic pathways. Among these, 6-formylpteridin-4-one derivatives have garnered particular attention due to their ability to act as precursors in the synthesis of nucleic acid components and other bioactive molecules.

The acetamido group at the 2-position of the pteridine ring introduces a polar amide functionality, enhancing the solubility and reactivity of the compound. This feature makes 2-Acetamido-6-formylpteridin-4-one a versatile building block for medicinal chemists seeking to develop novel drug candidates. The formyl group at the 6-position further contributes to its reactivity, allowing for further functionalization through condensation reactions, alkylation, or oxidation processes.

Recent advancements in computational chemistry and molecular modeling have highlighted the potential of 2-Acetamido-6-formylpteridin-4-one as a scaffold for drug design. Studies have demonstrated that modifications to this core structure can lead to compounds with enhanced binding affinity to target proteins and enzymes. For instance, virtual screening campaigns have identified derivatives of this compound that exhibit inhibitory activity against enzymes implicated in inflammatory diseases and cancer progression.

In the realm of medicinal chemistry, 2-Acetamido-6-formylpteridin-4-one has been explored as a precursor for synthesizing analogs with specific biological activities. Researchers have leveraged its structural framework to develop molecules with potential applications in treating neurological disorders, infectious diseases, and metabolic conditions. The formyl group, in particular, has been utilized to create Schiff bases and other heterocyclic compounds that exhibit notable pharmacological properties.

The synthesis of 2-Acetamido-6-formylpteridin-4-one typically involves multi-step organic reactions starting from readily available pteridine derivatives. Advanced synthetic methodologies, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity. These synthetic strategies not only facilitate the production of this compound but also provide insights into its structural flexibility and reactivity patterns.

From a biochemical perspective, 2-Acetamido-6-formylpteridin-4-one has been investigated for its role in enzymatic pathways involving pteridine metabolism. Studies suggest that derivatives of this compound may modulate the activity of enzymes such as tetrahydrobiopterin reductase (BH4R) and GTP cyclohydrolase I (GCH1), which are crucial in biosynthetic pathways related to neurotransmitter production and cellular redox balance.

The growing interest in natural product-inspired drug discovery has also prompted research into biologically active pteridine derivatives derived from 2-Acetamido-6-formylpteridin-4-one. By incorporating elements from plant-derived pterins or microbial metabolites, scientists aim to develop novel therapeutic agents with improved efficacy and reduced toxicity. Such efforts align with global trends toward sustainable drug development practices that emphasize natural product-inspired chemotypes.

Future research directions may focus on exploring the pharmacokinetic properties of 2-Acetamido-6-formylpteridin-4-one derivatives using preclinical models. Understanding how these compounds are absorbed, distributed, metabolized, and excreted will be essential for optimizing their therapeutic potential. Additionally, investigating their interactions with biological targets at the molecular level will provide critical insights into their mechanisms of action.

In conclusion,2-Acetamido-6-formylpteridin-4-one (CAS No. 29769-49-1) represents a compelling compound with significant implications in pharmaceutical research and drug development. Its unique structural features offer opportunities for designing molecules with tailored biological activities, making it a valuable asset in the quest for novel therapeutic interventions across various disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)